Quick Facts on Alveofact Uses

• Therapeutic Domain: Neonatal Respiratory Care
• Primary Use: Management of Respiratory Distress Syndrome (RDS) in premature infants.
• Prophylactic Use: Administration to premature infants who present with a high risk of developing RDS.

---

What Alveofact Treats: Main Uses and Benefits

Alveofact is a prescription medicine that is authorized for use in the clinical setting for newborns. Its primary role involves the management and supportive care of premature infants who are experiencing Respiratory Distress Syndrome (RDS), also known as hyaline membrane disease. This condition is associated with a deficiency of natural lung surfactant, which is necessary to assist the air sacs (alveoli) in remaining open during breathing.

Its therapeutic action is intended to supply or replenish insufficient surfactant in the lungs of these fragile patients. This support aims to facilitate lung function and help manage the breathing difficulties that characterize RDS. It may be administered as a treatment once RDS is diagnosed or as an early intervention for premature infants at elevated risk of developing the syndrome.

The use of surfactant replacement therapy, in general, has been a key factor in advancing neonatal intensive care for this patient population.

Who Can and Cannot Use Alveofact? (Eligibility Profile)

Official regulatory information defines the specific patient population eligible for Alveofact (bovactant) and lists explicit exclusions and restrictions for use. The medicine is strictly indicated for premature neonates/infants for the treatment or prevention of Respiratory Distress Syndrome (RDS).

Absolute Exclusion (Contraindication)

Alveofact must not be administered to infants with a known hypersensitivity (allergy) to the active substance, which is the phospholipid fraction from bovine lung, or to any of the listed inactive ingredients.

Eligibility Constraints and Restrictions

Constraint Area	Official Regulatory Status
Age/Condition	Use is not applicable for older children, adolescents, or adults.
Birth Weight	Safety and effectiveness have not been established in clinical trials for infants with a birth weight less than 600 g or greater than 1750 g.
Clinical Setting	Administration is restricted to settings where adequate facilities for ventilation and constant monitoring of premature neonates are immediately available.
Comorbidities	Use requires caution when the infant has suspected connatal pneumonia or congenital infections as the benefits have not been fully elucidated.

The official eligibility criteria are highly focused, ensuring the drug is used only in the specific neonatal population and clinical environment where its effect has been studied and approved by regulatory authorities.

Interactions with other medicines and products

Official regulatory information for Alveofact (Bovactant) confirms that the drug’s interaction profile is characterized by the absence of documented substance-specific interactions.

Interaction Scope

Category	Regulatory Status
Medicinal product categories with documented interactions:	None documented.
Specific interacting medicines (if explicitly listed):	None documented.
Mechanistic basis of interactions:	Not applicable; no substance-related interactions are known.
Timing-based interaction rules:	Not applicable; no mandatory administration separation requirements are documented.
Interaction-related restrictions:	None documented; no formal "do-not-combine" rules based on interaction risk are specified in the label.

Interaction Classifications

Category	Regulatory Status
Interaction severity classification:	Not applicable; no interactions are classified (e.g., contraindicated, major, moderate).
Interaction-context constraints:	None documented (e.g., no constraints related to food, alcohol, or herbal products).

Official Interaction Statements

The regulatory documentation states that no substance-related interactions with other medicinal products are known for Alveofact. Consequently, the official prescribing information provides no data on metabolic (pharmacokinetic) interactions, such as those involving enzyme or transporter systems. The product label does not specify any substances or categories that are contraindicated or require restricted co-administration due to documented interaction risk. This classification reflects the current status of interaction testing and documentation accepted by government health authorities.

The action of Alveofact (Bovactant) is defined by a biophysical mechanism focused entirely on governing the surface forces within the lung structures, independent of classical chemical receptor systems.

Physical Reduction of Alveolar Surface Tension

This mechanism involves the Bovactant components—essential phospholipids and Surfactant Proteins (SP-B/SP-C)—physically adsorbing to the Alveolar Air-Liquid Interface. This physical act breaks the high cohesive forces between water molecules, dramatically reducing the surface tension that causes alveolar collapse (atelectasis). This initiates a mechanistic cascade that alters the tissue's recoil properties.

---

️ Modulation of Pulmonary Compliance

The consequence of reduced surface tension is the direct modulation of pulmonary compliance and elastance. By eliminating the high recoil pressure that normally collapses the alveoli, the mechanism allows the lung tissue to inflate more easily. This physiological adjustment facilitates the maintenance of Functional Residual Capacity (FRC) and modulates the physiological conditions governing pulmonary gas exchange while lowering the muscular effort associated with generating tidal volume.

How to Use Alveofact: Administration Guidelines

Alveofact is a specialized pulmonary surfactant replacement exclusively administered to neonates/premature infants in a critical care setting. The medicine is supplied as a powder and solvent and requires aseptic reconstitution to form a suspension prior to use, following detailed mixing and waiting instructions.

Administration Route and Dosing

The required method of administration is endotracheopulmonary instillation, which delivers the medicine directly into the lungs via a tube in the patient's windpipe. Dosing is calculated based on the infant's body weight, with a labeled initial dose often set at 108 mg total phospholipids per kilogram of body weight (108 mg/kg BW).

For prophylaxis, the initial dose is given within the first hour after birth. For treatment of established symptoms, it is administered as quickly as possible upon diagnosis. Subsequent doses are not routine; if needed, they may be given at specific intervals, typically 12 to 24 hours apart, and the total cumulative dose must not exceed 216 mg/kg BW over the acute treatment course.

Procedural Conditions

Instructions for use describe specific procedural steps: tracheal aspiration is required before administration to clear the airway. Following the delivery of the suspension as a bolus, the infant is gently turned side-to-side for a few seconds to ensure the medicine is evenly distributed throughout the lung parenchyma. This structured protocol ensures the medicine is used consistently with labeled instructions.

Research Evidence / Overview of Studies for Alveofact

---

Evidence Base for Respiratory Distress Syndrome (RDS) in Premature Infants

Research on Alveofact primarily was studied for Respiratory Distress Syndrome (RDS). Studies conducted during periods of acute respiratory need for these patients have largely taken the form of Randomized Controlled Trials (RCTs), which was evaluated in studies observing patient cohorts. These RCTs compare Alveofact to either standard supportive care or to other similar natural surfactant medicines. Research examined outcomes related to physical discomfort and systemic imbalance, such as the duration of time infants needed support from a breathing machine, and whether they needed a repeat dose of the medicine.

Studies monitored key physiological strain outcomes, including the infant’s survival rate and the incidence of Chronic Lung Disease (CLD). Findings describe patterns observed in the studies. Research highlights changes measured during the study period, examining whether treatment with Alveofact was associated with changes in respiratory support needs. However, the certainty remains low when comparing Alveofact directly to specific alternative natural surfactants across the full range of measured outcomes.

Prophylactic and Early Rescue Treatment Studies

Studies monitored how outcomes related to systemic or functional imbalance were measured in observed populations based on the timing of administration. Research has explored short-term symptom changes when the medicine was studied for prophylactic use (very early, as a prevention for infants at high risk of RDS) or as an early treatment after breathing difficulties have already begun. The findings describe patterns related to early intervention strategies, which was observed in some studies.

---

Research into Acute Respiratory Distress Syndrome (ARDS) in Adults

Alveofact has also been studied for the use of surfactant replacement in Acute Respiratory Distress Syndrome (ARDS) in adults. Studies primarily examined outcomes related to physiological strain or stress, such as 28-day mortality and changes in blood oxygen levels. Findings were mixed across the pooled literature when research examined outcomes related to adult mortality and ventilator days. The data for this indication are still emerging, and research is ongoing.

---

Evidence Gaps and Areas of Uncertainty

Several key limitations exist in the research landscape for Alveofact. Comparative evidence is lacking in the form of large, definitive, head-to-head RCTs designed to provide insight into how outcomes compare against all alternative natural surfactants for major long-term outcomes. Long-term effects are not fully established, as follow-up durations were limited in many initial studies, leaving limited information for outcomes beyond the first year of life.

Common questions about Alveofact (FAQ)

---

Q: Can Alveofact be used for anything else besides its main purpose?

Official regulatory documents indicate that Alveofact is officially indicated only for the treatment or prevention of Respiratory Distress Syndrome (RDS) in premature infants. Its safety and effectiveness have not been established or approved for any other conditions in the official regulatory labeling.

---

Q: Do many people experience the 'common' side effects listed for Alveofact?

Official labeling does not provide a frequency (such as 'common' or 'rare') for the transient events that can occur during administration, like a temporary slowing of the heart rate (bradycardia) or decreased oxygen levels. The frequency of serious reported events, like cerebral or pulmonary hemorrhage, is consistent with rates typically observed in this high-risk patient population.

---

Q: How long can a person typically stay on Alveofact?

Alveofact is designed for an acute, short treatment course to stabilize the lungs. Subsequent doses, if clinically necessary, are usually given at intervals of 12 to 24 hours. The total amount of medicine administered is limited over this acute treatment period, according to official guidelines.

---

Q: Why is Alveofact not recommended for people with [official contraindication]?

The medicine is strictly contraindicated (must not be used) if a patient has a known hypersensitivity or allergy to the active substance derived from the bovine lung or any of the other ingredients. This is a safety measure due to the potential risk of severe allergic reactions that could occur.

---

Q: Does Alveofact contain any preservatives or common allergens?

The medicine's active material is derived from the phospholipid fraction of bovine (cow) lung, which is the substance linked to the main allergen risk (hypersensitivity). The solvent used for mixing the medicine contains a small amount of sodium. Official labeling does not list any common preservatives.

---

Q: Are there any long-term effects of using Alveofact?

Research tracking infants who received bovine surfactant therapy has generally been limited to follow-up periods of a few years. Studies generally found no evidence of major long-term side effects resulting from the therapy in the observed population, with treated infants showing no significant differences in growth or lung function during the study periods.

---

Q: Do any studies show how Alveofact affects long-term lung health?

Yes, long-term studies have specifically monitored key outcomes related to lung health, such as the incidence of Chronic Lung Disease (CLD). Findings from these follow-up studies, conducted up to 2.5 years of age, showed that the treatment did not significantly improve, and no adverse effects were observed on the developing respiratory system in the study populations.

---

Q: What is the difference between Alveofact and natural human surfactant?

Alveofact is classified as an exogenous natural surfactant because it is derived from the bovine (cow) lung phospholipid fraction. While it contains the essential Surfactant Proteins (SP-B and SP-C) needed for lung function, it is different from the surfactant naturally produced within the human body.

---

Q: Is the liquid form of Alveofact different from the powder form?

Alveofact is supplied as a powder and a separate solvent. The final 'liquid form' is the suspension that is created when the powder and solvent are mixed (reconstituted) precisely according to the preparation instructions. This preparation must happen immediately prior to the medicine being administered into the patient's lungs.

---

Q: How quickly does Alveofact start to show its intended effect?

The medicine’s effect is generally considered rapid because its mechanism is biophysical, immediately acting to stabilize the air sacs in the lungs. Regulatory safety data mentions that immediate and rapid changes in blood carbon dioxide ( pCO2) levels may lead to corresponding changes in laboratory values within the first few hours following its instillation.

---

Q: Can Alveofact affect my sleep schedule?

Official regulatory documents and the safety profile for this medicine do not list any effects on sleep or the sleep schedule among the known or reported systemic side effects.

---

Q: If I have a history of [general condition], can I still use Alveofact?

Alveofact is strictly for use in premature neonates, and its eligibility profile is very specific. Conditions such as metabolic or respiratory acidosis are recommended to be corrected before administration, as per official guidelines. Use also requires special caution if congenital pneumonia or certain renal (kidney) dysfunction is present.

---

Q: Does Alveofact cause weight gain?

Official regulatory documents do not list weight gain as a known or reported side effect of Alveofact.

---

Q: Does Alveofact affect laboratory test results?

Official information confirms that no substance-specific interactions that would interfere with standard laboratory tests are known. However, because the drug is intended to rapidly improve the patient's breathing and gas exchange, it may lead to corresponding changes in laboratory values like blood carbon dioxide ( pCO2).

---

Q: Is Alveofact commonly used in other countries besides the US?

Yes, Alveofact is a medicine that is approved for use by regulatory authorities in multiple countries and regions, including those in Europe and Africa, confirming its international presence.

---

Q: Are the effects of Alveofact permanent after stopping its use?

Alveofact is classified as a temporary replacement therapy designed to stabilize the lung mechanics only during the acute phase of illness until the infant can produce enough of its own natural surfactant. Follow-up studies found no significant long-term impact on the developing respiratory system, which suggests the biophysical effect is not permanent.

---

Q: What if Alveofact doesn't seem to be working?

In the event of an inadequate initial response, the official label provides guidance that a second dose may be rapidly administered, or subsequent doses may be given at 12 to 24 hour intervals. This decision is made by the medical team based on the patient's clinical status.

---

Q: Can Alveofact be used if someone has a kidney or liver problem?

Official labeling notes that the effectiveness of the medicine may be reduced if the infant has compromised pulmonary function due to conditions like congenital renal (kidney) dysfunction. The regulatory information does not provide specific details regarding primary liver problems.

---

Q: Does using Alveofact mean I can skip other treatments?

No. Alveofact is an essential part of a critical care regimen. It is a supportive treatment that is used in conjunction with other established critical care procedures, such as mechanical ventilation and constant monitoring.

---

Q: Are there any warnings about sunlight exposure while using Alveofact?

Official regulatory documents, including the safety profile and warnings, do not list any special precautions regarding sunlight exposure or potential photosensitivity related to the use of Alveofact.

---

Q: What if I take another medicine that causes the same side effect as Alveofact?

The product label states that no substance-specific (metabolic) interactions with other medicines are known. However, Alveofact is administered in a critical care setting where the clinical team must carefully manage all treatments to prevent additive effects, such as combining two drugs that might both cause a temporary decrease in heart rate.

Storage Conditions and Requirements

Alveofact (powder and solvent) must be stored at a temperature below 30 C and must not be frozen [1]. This freezing restriction applies to the powder, the solvent, and the final reconstituted suspension [1]. The medicine must be kept out of the sight and reach of children and should not be used past the labeled expiry date [1].

Stability After Reconstitution	Condition
Up to 6 hours	At temperatures up to 25 C
Up to 24 hours	When refrigerated (2 C to 8 C)

If the suspension is refrigerated, the vial or syringe must be subject to a gentle swirling motion once before use [1].

Disposal Instructions

Unused or expired Alveofact must be disposed of according to local regulations for pharmaceutical waste [1]. It is officially prohibited to dispose of the product via wastewater or with ordinary household waste [1].